Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

06/07/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.29%, closing at 53055.91 points; the Nasdaq Composite rose by 1.12%, closing at 26121.16 points; the S&P 500 Index rose by 0.72%, closing at 7537.43 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

UTime Limited Class A: Overnight gain 171.5%, Surges Amid Nasdaq Ticker Change and Web3 Acquisition Strategy Shift

**UTime Limited Class A** UTime Limited is an exempted limited liability company incorporated in the Cayman Islands on October 9, 2018. The Company is dedicated to delivering cost-effective mobile devices to consumers worldwide, with a strategic focus on bridging the digital divide by enabling low-income populations in both developed markets — including the United States — and high-growth emerging markets such as India, South Asia, and Africa to access the latest mobile technologies. The Company's core business operations encompass the design, research and development, manufacturing, sales, and brand management of mobile handsets, accessories, and related consumer electronics products.

**UTime Limited Class A (FXHO) Surges on Nasdaq Ticker Change and Web3 Acquisition Plans** Shares of UTime Limited Class A (FXHO) have experienced a sharp rally, driven by the company's official Nasdaq ticker symbol change from "WTO" to "FXHO," a corporate action that has drawn significant market attention. The rebranding is directly linked to the company's planned acquisition of Web3 data platform Feixiaohao Technology Inc., a blockchain and cryptocurrency intelligence provider serving millions of users globally. The market's heightened enthusiasm reflects growing investor confidence in UTime Limited Class A (FXHO)'s strategic pivot from traditional consumer electronics toward Web3 infrastructure and digital asset ecosystems. Reinforced by constructive signals from management, the stock surged 77.78% in after-hours trading to $12.80 per share, with the latest gain reaching an impressive 171.5%, underscoring robust investor appetite for the company's transformative repositioning strategy.

Seer, Inc. Class A: Overnight gain 35.2%, Surges Amid Privatization Bid, Shareholder Support, and Key IP Victories

**Seer, Inc. Company Overview** Seer, Inc. (Class A) was incorporated in the State of Delaware on March 16, 2017, in accordance with applicable state statutes. The Company is dedicated to empowering researchers with deep, unbiased biological insights through the commercialization of its transformative product portfolio, with the overarching mission of advancing scientific excellence. The Company's flagship offering, the Proteograph™ Product Suite, leverages proprietary engineered nanoparticle technology to enable unbiased, in-depth, rapid, and large-scale data acquisition across the full proteome. Designed as a fully integrated end-to-end solution, the Suite encompasses three core components: consumables, automated instrumentation, and software. The platform's streamlined workflow facilitates proteomics analysis across thousands of samples, enabling comprehensive characterization of proteomic complexity and dynamic biological processes. The Proteograph™ Product Suite is engineered to be broadly compatible with virtually all laboratory environments, positioning the Company to address the growing demand for scalable and accessible proteomics solutions across both academic and commercial research settings.

**Seer, Inc. Class A (SEER) Surges 35.2% on Privatization Bid and IP Developments** Shares of Seer, Inc. Class A (SEER) rallied 35.2% in a single session, driven by a confluence of catalysts. Chairman and CEO Dr. Omid Farokhzad submitted a non-binding going-private proposal to acquire all outstanding Class A common shares at $2.45 per share in cash, plus two separate contingent value rights (CVRs), triggering immediate market expectations of a premium exit. Concurrently, the Radoff-JEC Group publicly expressed support for a company sale, aligning with management's position and materially elevating deal-closing expectations. Further bolstering sentiment, multiple intellectual property milestones reinforced the company's technological moat: the European Patent Office upheld patent EP4056263, the ITC initiated an infringement investigation against Nanomics, and the PTAB sustained key claims of a U.S. patent — collectively providing fundamental valuation support amid the broader deal-driven momentum.

YD Bio Limited: Overnight gain 23.2%, Surges Amid Lab License Expansion, Strategic Transformation, and Merger Catalyst

**YD Bio Limited Incorporated in Cayman Islands, Targeting High-Unmet-Need Therapeutic Areas with Innovative Biopharmaceutical Pipeline** YD Bio Limited (the "Company") was formally incorporated in the Cayman Islands on February 6, 2024, establishing itself as a biopharmaceutical enterprise dedicated to advancing next-generation therapeutic and diagnostic solutions. The Company's core business operations encompass the research and development of blood-based cancer detection technologies, alongside the advancement of stem cell and exosome-based therapeutic modalities. YD Bio Limited is committed to delivering breakthrough treatment options targeting diseases with significant unmet medical needs, while concurrently serving the broader pharmaceutical industry as a reliable supplier of clinical laboratory reagents and compounds. Central to the Company's commercial strategy is the cultivation of strategic biopharmaceutical partnerships, designed to facilitate the translation of proprietary innovative technologies into commercially viable pharmaceutical products and cancer diagnostics. This partnership-driven model positions YD Bio Limited to accelerate the path from early-stage research to market-ready solutions, addressing critical gaps across multiple therapeutic and oncological diagnostic segments.

**YD Bio Limited (YDES) Surges 23.2% on Regulatory Expansion and Strategic Repositioning** Shares of YD Bio Limited (YDES) advanced 23.2% in a single trading session, driven by a confluence of positive catalysts. The company's subsidiary, EG BioMed US Inc., secured out-of-state clinical laboratory licenses in Rhode Island (clinical genetics) and Pennsylvania (clinical chemistry and hematology) — two of the most stringently regulated jurisdictions in the United States — expanding its authorized operating coverage to 46 states, the District of Columbia, and Guam. The licensing expansion meaningfully broadens market access for multi-cancer blood-based diagnostic services, including pancreatic and colorectal cancer screening, enhancing near-term commercialization prospects. Additionally, CEO Dr. Ethan Shen outlined a strategic transformation roadmap toward a **"clinical molecular data platform biotechnology company."** These developments, compounded by the previously disclosed planned merger with EG BioMed targeted for completion in 2026, collectively fueled the sharp single-day rally.

Criteo SA Sponsored ADR Repr 1 Sh: Overnight gain 21.4%, Surges Amid Earnings Beat, AI-Driven Ad Growth, and Retail Media Momentum

**Criteo S.A. – Company Overview** Criteo S.A. (incorporated under French law on November 3, 2005) is a global commerce media company dedicated to empowering marketers and media owners to drive superior commerce outcomes. By converging commerce data with advanced artificial intelligence capabilities, the Company bridges the ecosystems of e-commerce, digital marketing, and media monetization, delivering comprehensive coverage across the full consumer shopping journey. Leveraging its open internet infrastructure, Criteo provides premium marketing and monetization solutions that enable brands, retailers, and media owners to accelerate business growth. To date, the Company has generated approximately **$30 billion** in commerce value for its clients, encompassing diverse revenue streams including product sales proceeds and advertising revenues.

**Criteo SA Sponsored ADR Repr 1 Sh (CRTO) Surges 21.4% Overnight on Strong Earnings Beat** Shares of Criteo SA Sponsored ADR Repr 1 Sh (CRTO) posted a remarkable single-session overnight gain of 21.4%, bringing year-to-date cumulative appreciation to 12.4%. The sharp upside move is broadly consistent with typical post-earnings market reactions following a significant beat against consensus expectations. As an AI-powered commerce media company, Criteo SA Sponsored ADR Repr 1 Sh (CRTO) leverages artificial intelligence to bridge e-commerce and digital advertising ecosystems, prompting investors to reassess its advertising delivery and media monetization capabilities. The company's deepening presence in the **retail media network** segment continues to benefit from robust sector momentum, while a broader recovery in open internet advertising has driven increased ad spending from both brands and retailers, directly lifting revenue expectations. The convergence of solid year-to-date fundamental trends and today's accelerated price action reinforces the bullish market sentiment.

SharonAI Holdings, Inc. Class A: Overnight gain 17.7%, Surges After Completing Billion-Dollar Strategic Financing, Boosting AI Growth Outlook

**SharonAI Holdings, Inc. Class A (SHAZ) Surges 17.7% in After-Hours Trading Following $1.6 Billion Strategic Financing Completion** SharonAI Holdings, Inc. Class A (SHAZ) emerged as a standout performer in Monday's after-hours session, surging 17.7% to $76.01 per share, ranking among the top gainers during the extended trading period. The stock's year-to-date cumulative gain has now reached a remarkable 4,108.4%. The primary catalyst behind this sharp move was the company's official completion of a $1.6 billion strategic financing round announced on Monday. The closing of this substantial capital raise signals strong conviction from external strategic investors regarding SharonAI Holdings, Inc. Class A (SHAZ)'s AI business prospects. The proceeds are expected to accelerate the company's technology research and development initiatives alongside broader business expansion efforts, reinforcing market confidence and driving sustained capital inflows into the stock.

Alight, Inc. Class A: Overnight gain 17.2%, Surges Amid Oversold Rebound Driven by Valuation Recovery and Strong Fundamentals

**Alight, Inc. Class A: Company Overview** Alight, Inc. (incorporated in the State of Delaware on September 12, 2018) is a leading provider of integrated cloud-based human capital solutions, specializing in assisting employers and their workforces in managing health, wealth, and human resources needs. Underpinned by more than 25 years of operational history and deep domain expertise, the Company is well-positioned to address the complex demands of modern enterprises and an evolving workforce. The Company currently serves approximately 3,000 employers, including 66 of the *Fortune* 100 and 240 of the *Fortune* 500, delivering comprehensive services to 22 million current and former employees and their 18 million dependents. In fiscal year 2017, Alight processed in excess of 340 million benefits and human resources transactions, underscoring the scale and operational depth of its service platform.

**Alight, Inc. Class A (ALIT) Surges 17.2% Overnight on Oversold Rebound** Shares of Alight, Inc. Class A (ALIT) posted a notable overnight gain of 17.2%, driven primarily by an oversold rebound following a steep year-to-date decline of 57.1%. The selloff had compressed the company's market capitalization to approximately $449 million — a valuation widely viewed as disconnected from its underlying business fundamentals. The disconnect appears significant given Alight, Inc. Class A (ALIT)'s operational scale: the company serves nearly 3,000 employers, supports 22 million end users, and counts 240 Fortune 500 companies among its clients. As a leading provider of cloud-based human capital solutions, Alight, Inc. Class A (ALIT) processes over 340 million HR transactions annually. Market participants appear to be repositioning based on valuation recovery logic, with the technical rebound reflecting renewed confidence in the company's strong fundamentals relative to its compressed market valuation.

Orthofix Medical, Inc.: Overnight gain 16.4%, Surges Amid FDA Reclassification and Medicare Reimbursement Policy Restoration

**Orthofix Medical, Inc.: Company Overview** Orthofix Medical, Inc. is a limited liability company incorporated under the laws of Curaçao, originally established in the Netherlands Antilles on October 19, 1987. The company has since evolved into a globally recognized leader in the spine and orthopedics sector, offering a comprehensive portfolio that encompasses biologics solutions, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and surgical navigation systems. The company's broad product offering is designed to address the full spectrum of skeletal replacement and joint reconstruction needs across all patient demographics, enabling individuals to pursue more active and dynamic lifestyles. Orthofix Medical remains firmly committed to the design, development, manufacturing, and commercialization of musculoskeletal medical devices, with a primary focus on orthopedic applications. Through its diversified product pipeline and continued investment in innovation, Orthofix Medical is well-positioned to meet the evolving demands of the global orthopedic and spine market, delivering clinically differentiated solutions to healthcare providers and patients worldwide.

**Orthofix Medical, Inc. (OFIX) Surges 16.4% on Dual Regulatory Tailwinds** Shares of Orthofix Medical, Inc. (OFIX) posted a notable single-session gain of 16.4%, driven by two converging positive catalysts underpinning the company's core bone growth therapy franchise. First, the U.S. Food and Drug Administration implemented a reclassification of non-invasive bone growth stimulation products effective April 16, 2026, providing meaningful regulatory validation and enhanced market access for Orthofix Medical, Inc. (OFIX)'s flagship therapeutic offerings. Second, the reinstatement of Medicare reimbursement coverage has effectively reopened commercial monetization channels, broadening eligible patient populations and catalyzing a recovery in end-market demand. The convergence of these two favorable developments has materially improved investor sentiment surrounding the profitability outlook for Orthofix Medical, Inc. (OFIX)'s bone growth therapy segment, prompting a significant upward revision in earnings expectations and driving the sharp intraday price appreciation.

Enovis Corporation: Overnight gain 15.1%, Surges Amid Strong Earnings Beat and Strategic Catalysts Driving Valuation Recovery

**Enovis Corporation: A Innovation-Driven Medical Technology Growth Enterprise Committed to Clinical Excellence** Founded in 1995, Enovis Corporation is an innovation-driven medical technology growth company with a steadfast commitment to advancing clinically differentiated solutions. The Company is dedicated to developing and delivering cutting-edge offerings designed to optimize patient outcomes and enhance the efficiency of healthcare workflows. Underpinned by a continuously evolving global talent ecosystem and a deeply embedded culture of innovation, Enovis leverages its diversified product portfolio, specialized professional services, and integrated technology platforms to meaningfully improve and promote active lifestyles for patients across orthopedics and adjacent medical disciplines.

**Enovis Corporation (ENOV) Surges 15.1% Overnight Amid Strong Catalysts** Shares of Enovis Corporation (ENOV), a leading medical technology company specializing in orthopedic and clinically differentiated solutions, posted a remarkable single-session gain of 15.1% overnight, lifting its market capitalization to approximately $1.295 billion. Despite the sharp rally, the stock remains down 2.8% on a year-to-date basis. The significant price movement appears driven by a confluence of catalysts, including better-than-expected earnings results, notable product development milestones, or strategically positive corporate announcements. The upside was further amplified by accumulated valuation recovery potential stemming from the stock's prior relative underperformance, which attracted concentrated institutional buying activity. This surge in capital inflows magnified price elasticity, collectively contributing to the outsized single-day advance. Market participants will closely monitor whether the momentum is sustained as fundamentals continue to align with Enovis Corporation's (ENOV) long-term growth trajectory.

ChipMOS Technologies, Inc. Sponsored ADR: Overnight gain 13.4%, Surges Amid Rising Demand for Display Driver and Advanced Memory Packaging

**ChipMOS Technologies, Inc. – Company Overview** ChipMOS Technologies, Inc. was incorporated on July 28, 1997, and operates as a specialized provider of back-end semiconductor assembly and testing services. The Company's core business encompasses a comprehensive suite of offerings, including wafer probing, final testing, leadframe and organic substrate packaging and assembly, gold bump fabrication, and turnkey flip-chip services, catering to both memory and logic/mixed-signal semiconductor segments. ChipMOS primarily serves the display driver semiconductor and advanced memory product markets, positioning itself as a key enabler within the global semiconductor supply chain's downstream value-added services sector.

**ChipMOS Technologies, Inc. Sponsored ADR (IMOS) Surges 13.4% Overnight, Posting 151.2% Year-to-Date Gain** ChipMOS Technologies, Inc. Sponsored ADR (IMOS) recorded a notable overnight surge of 13.4%, bringing its year-to-date cumulative gain to an impressive 151.2%, underpinned by a confluence of strengthening fundamental drivers. The company, specializing in display driver semiconductor packaging and testing as well as advanced memory packaging, is capitalizing on a broad-based recovery across global smartphone, automotive display, and TV panel markets, fueling sustained demand growth for driver IC packaging and testing services. Concurrently, the accelerating AI and high-performance computing megatrend has materially revitalized memory market conditions, driving a significant uptick in order volumes. ChipMOS Technologies, Inc. Sponsored ADR (IMOS) further reinforces its competitive positioning through high-value-added advanced packaging technologies, including gold bump fabrication and flip-chip solutions, aligning strategically with prevailing industry evolution trends.

IREN Limited: Overnight gain 13.1%, Surges Amid Key Executive Appointments and Anthropic Data Center Partnership Prospects

**IREN Limited: Company Profile** IREN Limited (the "Company") was incorporated on November 6, 2018, under the laws of New South Wales, Australia. The Company is a dedicated Bitcoin mining enterprise focused on the development, ownership, and operation of data centers and power infrastructure predominantly powered by renewable energy sources. The Company strategically targets regions characterized by low-cost energy environments, abundant resource availability, and favorable renewable energy profiles, positioning itself to capitalize on competitive operational advantages within the digital asset mining sector. IREN's mining operations are conducted through the deployment of application-specific integrated circuit ("ASIC") computing hardware, generating revenue through the receipt of block rewards and transaction fees denominated in Bitcoin. As part of its treasury management strategy, the Company converts its daily Bitcoin proceeds into fiat currencies, including the U.S. dollar (USD) and the Canadian dollar (CAD), thereby facilitating the realization of revenues in conventional monetary terms.

**IREN Limited (IREN) Surges 13.1% on Executive Appointments, Anthropic Data Center Speculation** Shares of IREN Limited (IREN) rallied 13.1% in a single session, driven by multiple catalysts. The company announced two high-profile executive appointments: Kambiz Aghili, former Vice President of Oracle Cloud Infrastructure Products, has been named Chief Product Officer, while veteran data center specialist Michael Nudelman joins as Chief Development Officer — both moves reinforcing IREN's AI cloud platform strategy. Additionally, the Australian Financial Review reported that Anthropic is seeking over 1.4 gigawatts of Australian data center capacity, valued at approximately USD 12–15 billion, with IREN reportedly shortlisted as a candidate. The rally was further supported by broad-based strength across crypto mining peers — Terawulf surging over 17% — alongside improved macro risk appetite, with Nasdaq futures advancing 1.11%, compounded by technical mean-reversion demand following prior overselling. Consensus analyst price target stands at **USD 81.75**, with a **Buy** rating.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.